Don’t miss Five Alarm Bios' interview with Mike Scialom at Cambridge Independent to learn more about Five Alarm Bio's pioneering research into minimising the effects of ageing.
CEO Dr Janette Thomas, spoke with Mike Scialom at Cambridge Independent to discuss this years’ exciting advances in their mission to develop treatments for a range of age-associated diseases and disabilities, introducing their innovative small molecule approach aimed at extending the healthy lifespan of cells.
Read the article here: Five Alarm Bio has anti-ageing drug agenda firmly in its sights (cambridgeindependent.co.uk)
Five Alarm Bio are delighted to have the support from Cambridge investors Meltwind Advisory LLP, o2h Ventures, and Cambridge Angels, and there is still the opportunity to join their seedfunding round as they move towards their next phase of ageing research. Please contact them: janette@fivealarmbio.com or see their website www.fivealarmbio.com
